Prescription drug abuse is a serious public health problem that has reached crisis levels across the United States. The governors of five New England states met earlier this week to discuss how to combat prescription drug abuse and diversion. The American Medical Association hopes they will focus on a five-pronged comprehensive, public health approach that emphasizes treatment and prevention.
Kenneth Blum, PhD, President and CEO of IGENE, LLC, has long been associated with leading drug monitoring laboratory Dominion Diagnostics in a scientific research and advisory role. Blum, who sits on Dominion’s Addiction and Scientific Advisory Board, was recently appointed Chief Scientific Advisor to Dominion Diagnostics.
Dominion Diagnostics, a leading national provider of drug testing, medication monitoring, and clinical support services, launched new testing today that will detect Kratom use. Dominion’s Kratom assay will expand the company’s designer drug testing menu, which already includes detection of synthetic cannabinoids (Spice/K2) and synthetic cathinones (bath salts).
Dominion Diagnostics is pleased to announce its renewed commitment to support education and advancement in addiction medicine and behavioral healthcare. For its second consecutive year, Dominion is the Series Thought Leadership Partner for the 2014 Addiction Professional Panel Series hosted by Vendome Healthcare Media.
Dominion Diagnostics, a leading national provider of clinical drug testing and medication monitoring services, is uniting with other donors in the business community to raise funds for the victims of the Boston Marathon bombings.
Dominion Diagnostics, a leading national provider of clinical drug testing and medication monitoring services, will sponsor a year-long series of regional educational Lunch’n’Learns hosted by Addiction Professional, a magazine published for the addiction treatment field by Vendome Healthcare Media.
Leading national drug testing and medication monitoring company Dominion Diagnostics has launched new, more sensitive, and more relevant testing to detect synthetic cathinones or “bath salts” in urine. Designed by Dominion’s Research and Development team, the test will detect five synthetic cathinones: mephedrone, 3,4-methylendioxypyrovalerone (MDPV), methylone, butylone, and ethylone. The testing, performed by liquid c
Dominion Diagnostics, LLC, a leading national medication and substance use monitoring company, is celebrating its fifteenth year in business providing quality monitoring services, clinical support and education to improve patient outcomes in addiction treatment and pain management.
